Literature DB >> 2295454

Correlation between measured creatinine clearance and calculated creatinine clearance in ovarian cancer patients.

J T Chambers1, S K Chambers, P E Schwartz.   

Abstract

In 84 patients with advanced ovarian cancer, the measured 24-hr urinary creatinine clearance and a calculated creatinine clearance were compared prior to cis-platinum-based chemotherapy. The overall correlation between the two methods was excellent, using Pearson's coefficient of correlation test, r = 0.508 and P less than 0.000001. In a subset of 59 patients with adequate 24-hr urine collections, analysis showed a correlation of r = 0.526 and P = 0.000018. Furthermore, in this group of patients using a creatinine clearance of 45 ml/min as a threshold for dose adjustment, there was only a 3.3% error in accepting the calculated creatinine clearance for the measured creatinine clearance. In summary, in patients with advanced ovarian cancer, even in the postoperative state, an evaluation of renal function with a calculated creatinine clearance prior to chemotherapy is sufficient.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295454     DOI: 10.1016/0090-8258(90)90110-7

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Predicting genitourinary toxicity in patients receiving cisplatin-based combination chemotherapy: a Cancer and Leukemia Group B study.

Authors:  J B Hargis; J R Anderson; K J Propert; M R Green; D A Van Echo; R B Weiss
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer.

Authors:  Bercin Kutluk Cenik; Han Sun; David E Gerber
Journal:  Lung Cancer       Date:  2013-03-15       Impact factor: 5.705

3.  Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients.

Authors:  M J Dooley; S Singh; D Rischin
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.